- March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
- October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
- April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
- March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
- October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
- March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctorsPrimary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
- March 21, 2014 - Identification of Novel, Efficacious F508del‐CFTR Correctors to Treat Cystic Fibrosis
- October 14, 2013 - Next generation F508del CFTR correctors using a YFP based high throughput screening assay
- October 14, 2013 - Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
- October 14, 2013 - A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
More posters |
October 14, 2013 Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
Joan P. Blonder, ,Nancy L. Quinney, Peter Bove, Doug Looker, Xicheng Sun, Martina Gentzsch, Charles Scoggin and Sherif E. Gabriel
Intestinal current measurement (ICM) in rectal biopsies is merging as a valuable diagnostic and efficacy parameter for cystic fibrosis (CF). ICM may facilitate CF
identification or genotype classification, when more traditional tests such as sweat chloride or FEV1 are equivocal. ICM also has been shown to be a valuable tool for assessment of CFTR dysfunction and pharmacological modulation of CFTR in CF mouse models.
In this study, ICM was used to explore F508del-CFTR corrector activity of a novel small molecule inhibitor of S-nitrosoglutathione reductase (GSNOR). GSNOR regulates intracellular levels of S-nitrosoglutathione (GSNO), recognized as an important molecule in CF via its ability to influence CFTR maturation and function. More…(481Kb)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
